Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck said it had stopped Gardasil shipments to China from this month. The company has previously said China's anti-bribery and anti-corruption drive had also hurt sales of the vaccine.

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. Shares of Merck ...